Fill-Finish Pharmaceutical Contract Manufacturing Market Report 2026

The fill-finish pharmaceutical contract manufacturing market size has grown strongly in recent years. It will grow from $13.03 billion in 2025 to $14.25 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to growing demand for outsourced pharmaceutical manufacturing, limited in-house fill-finish capabilities, rising biologics and vaccine production, cost pressures on pharmaceutical companies, expansion of sterile manufacturing facilities.

The fill-finish pharmaceutical contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $20.46 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing adoption of prefilled syringes and vials, growth in global biologics market, technological advancements in fill-finish processes, expansion of contract manufacturing in emerging markets, stricter regulatory requirements for sterile manufacturing. Major trends in the forecast period include contract manufacturing expansion, increasing biologics production, prefilled syringe adoption, cold chain logistics optimization, regulatory compliance and quality assurance.

The rising demand for pharmaceutical products is anticipated to drive the growth of the fill-finish pharmaceutical contract manufacturing market in the coming years. Pharmaceutical products include drugs and medications formulated to diagnose, prevent, treat, or cure diseases and medical conditions in humans or animals. Fill-finish pharmaceutical contract manufacturing plays a vital role in the aseptic filling of injectables, biologics, and other drug products, ensuring precision, regulatory compliance, and efficient manufacturing workflows while maintaining high product quality standards. For example, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations, a Belgium-based trade association representing the pharmaceutical industry in Europe, total pharmaceutical production in Europe reached €390.0 billion ($422,803 million) in 2023, increasing from €363.3 billion ($393,857 million) in 2022. As a result, the growing demand for pharmaceutical products is contributing to the expansion of the fill-finish pharmaceutical contract manufacturing market.

Major companies operating in the fill-finish pharmaceutical contract manufacturing market are increasingly focusing on technological innovations such as automated aseptic micro-batch filling systems to improve production accuracy, lower contamination risks, and provide greater flexibility for handling a wide range of drug formulations. Automated aseptic micro-batch filling systems are advanced, robotics-based platforms that carry out highly precise filling and finishing operations within controlled environments, reducing human involvement while enhancing sterility assurance, reproducibility, and operational efficiency. For instance, in January 2023, Steriline s.r.l., an Italy-based company specializing in aseptic production solutions, introduced robotic technologies designed for small-batch aseptic filling. These systems offer increased safety and flexibility for manufacturing both toxic and non-toxic pharmaceutical products, while minimizing human error, improving product quality, and optimizing overall efficiency.

In October 2023, Sharp Services, LLC, a US-based biopharmaceutical services provider, acquired Berkshire Sterile Manufacturing for an undisclosed amount. Through this acquisition, Sharp aims to expand its capabilities in providing small- to medium-scale injectable services to the biopharmaceutical industry, strengthening its position as a contract development and manufacturing organization offering comprehensive fill-finish services. Berkshire Sterile Manufacturing is a US-based fill-finish contract development and manufacturing organization specializing in sterile injectable products.

Major companies operating in the fill-finish pharmaceutical contract manufacturing market are Thermo Fisher Scientific Inc., Fresenius Kabi, Eurofins Scientific SE, Lonza Group Ltd., Catalent Inc., West Pharmaceutical Services Inc., Patheon, Samsung Biologics Co.Ltd., WuXi Biologics, Piramal Pharma Solutions, Pfizer CentreOne, Recipharm AB, Emergent BioSolutions Inc., Boehringer Ingelheim BioXcellence, Corden Pharma GmbH, Aenova Group, Baxter BioPharma Solutions, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Rentschler Biopharma SE, Recro Pharma Inc., Cobra Biologics Limited, Grand River Aseptic Manufacturing (GRAM), MabPlex International Ltd., Cerbios-Pharma SA, Symbiosis Pharmaceutical Services Limited.

North America was the largest region in the fill-finish pharmaceutical contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fill-finish pharmaceutical contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fill-finish pharmaceutical contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the fill-finish pharmaceutical contract manufacturing market by increasing the cost of imported vials, syringes, and specialized equipment, disrupting supply chains and slowing production timelines. Segments like prefilled syringes and biologics vials are most affected, particularly in North America and Europe, which rely on imports from Asia-Pacific hubs. While tariffs have posed challenges, they have also encouraged local manufacturing investments and diversification of sourcing strategies, supporting long-term resilience in the market.

The fill-finish pharmaceutical contract manufacturing market research report is one of a series of new reports that provides fill-finish pharmaceutical contract manufacturing market statistics, including fill-finish pharmaceutical contract manufacturing industry global market size, regional shares, competitors with a fill-finish pharmaceutical contract manufacturing market share, detailed fill-finish pharmaceutical contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the fill-finish pharmaceutical contract manufacturing industry. This fill-finish pharmaceutical contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fill-finish pharmaceutical contract manufacturing involves outsourcing the final stages of the pharmaceutical production process to specialized contract manufacturing organizations (CMOs).

The main product types in fill-finish pharmaceutical contract manufacturing include prefilled syringes, vials, cartridges, and other products. Prefilled syringes are ready-to-use delivery systems that contain a pre-measured dose of medication and are aseptically filled through fill-finish pharmaceutical contract manufacturing processes to ensure accurate dosing, sterility, and high-quality standards. Fill-finish pharmaceutical contract manufacturing is also utilized for both large-molecule and small-molecule products by end users such as biopharmaceutical companies and pharmaceutical companies.

The fill-finish pharmaceutical contract manufacturing market includes revenues earned by entities by providing septic filling, packaging, labeling, and serialization services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.